Andrew Kim

Andrew Kim has 15+ years of experience in the medical device industry, focusing mainly on the structural heart space. Before joining ICS, Andrew was Director of Therapy Development at Mitralign, leading the EU tricuspid project. Prior, he was Sr. Manager of Operations & Clinical at Direct Flow Medical from the clinical study stage to commercialization of their TAVI system. He also brings experience from GDS (now Ancora Heart), Maya Medical (acquired by Covidien), Apama (acquired by Boston Scientific), and Imperial College London. Andrew’s background is in R&D. He was an engineer at Medtronic Endovascular, eValve (acquired by Abbott), and Crux Biomedical (acquired by Volcano Corp). He holds a BSci in biomedical engineering from Northwestern University.